Trials / Recruiting
RecruitingNCT06452706
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
The Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection in Human Epidermal Growth Factor Receptor 2 (HER2) Negative Recurrent/Metastatic Breast Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2102 for injection | TQB2102 for injection is a HER2 dual-antibody-drug conjugate (ADC). |
Timeline
- Start date
- 2024-11-14
- Primary completion
- 2026-06-01
- Completion
- 2028-06-01
- First posted
- 2024-06-11
- Last updated
- 2024-11-19
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06452706. Inclusion in this directory is not an endorsement.